RECRUITINGPhase 1INTERVENTIONAL
Limbal Stem Cell Derived Exosome (LSC-Exo) Eye Drop for Treatment of Dry Eye
A Clinical Study for Safety and Efficacy Evaluation of Limbal Stem Cell Derived Exosome (LSC-Exo) Eye Drop for Treatment of Dry Eye Syndrome
About This Trial
The purpose of this study is to determine the safety and efficacy of Limbal Stem Cells derived Exosomes (LSC-Exo) in alleviation of dry eye symptoms
Who May Be Eligible (Plain English)
Who May Qualify:
- Patients with complaints of burning or itching or feeling of a foreign body in the eye
- Moderate and severe dry eye severity
- Age between 18-70 years
Who Should NOT Join This Trial:
- Previous history of eye surgery
- Any disease that suppresses the immune system
- Pregnancy and breastfeeding
- Eyelid abnormalities
- Use of eye drops in the past year except artificial tears and lubricating ointments
- Use of systemic drugs that affect the tear film in last three months
- Use of contact lenses in the last three months
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Patients with complaints of burning or itching or feeling of a foreign body in the eye
* Moderate and severe dry eye severity
* Age between 18-70 years
Exclusion Criteria:
* Previous history of eye surgery
* Any disease that suppresses the immune system
* Pregnancy and breastfeeding
* Eyelid abnormalities
* Use of eye drops in the past year except artificial tears and lubricating ointments
* Use of systemic drugs that affect the tear film in last three months
* Use of contact lenses in the last three months
Treatments Being Tested
BIOLOGICAL
Limbal Stem Cell Derived Exosomes Eye Drop
Patients will receive artificial tears for 2 weeks to get the normalized baseline, followed by LSC-Exo eye drops 0.15 ml/single eye/one time, four times a day for 3 months. The follow-up visit will be 12 weeks since the administration of LSC-Exo eye drops.
Locations (1)
Moheb Kowsar Hospital
Tehran, Iran